首页> 外文期刊>BMC Urology >Measuring the improvement in health-related quality of life using King’s health questionnaire in non-obese and obese patients with lower urinary tract symptoms after alpha-adrenergic medication: a preliminary study
【24h】

Measuring the improvement in health-related quality of life using King’s health questionnaire in non-obese and obese patients with lower urinary tract symptoms after alpha-adrenergic medication: a preliminary study

机译:使用King的健康问卷调查在α-肾上腺素药物治疗后非肥胖和下尿路症状的肥胖患者中与健康有关的生活质量的改善:一项初步研究

获取原文
           

摘要

Background The efficacy of medical treatment among obese men with lower urinary tract symptoms (LUTS) has been less clear, especially regarding the improvement of QoL. We aimed to investigate the difference in efficacy and consequent satisfaction of life quality after medical treatment of male LUTS according to obesity. Methods An 8-week prospective study was performed for a total of 140 patients >50?years old with International Prostate Symptom Scores (IPSS) > 12 points and prostate volume > 20?mL. Obesity was determined by either body mass index (BMI) or waist circumference (WC). Patients were divided into 2 groups according to BMI or WC. Patients received tamsulosin at a dose of 0.4?mg daily for 8?weeks. The changes from baseline in the IPSS, maximal urinary flow rate (Qmax), post-void residual volume, questionnaire of quality of life (QoL), and King’s Health Questionnaire (KHQ) were analyzed. Results Of the 150 enrolled patients, 96 completed the study. Seventy-five patients (78.1%) had BMI ≥ 23?kg/m2, and 24 (25.0%) had WC > 90?cm. Overall, the IPSS, IPSS QoL, and total KHQ showed significant improvement. Obese (BMI ≥ 23?kg/m2) and non-obese (BMI 2) both showed improvement of the IPSS and IPSS QoL scores, but only the obese (BMI ≥ 23?kg/m2) group showed improvement of the total KHQ score (P 90?cm) group showed improvement of the IPSS and total KHQ scores (P Conclusions Our preliminary study showed the different efficacy of an alpha-blocker for improvement of LUTS and life quality according to obesity. Obese patients, defined by BMI or WC, showed the tendency toward a more favorable improvement of LUTS and life quality. Trial registration Current Controlled Trials 2010–058. Registered 2 September 2010 in Soonchunhyang Univeristy Hospital
机译:背景技术在下尿路症状(LUTS)的肥胖男性中,药物治疗的疗效尚不清楚,尤其是在QoL改善方面。我们的目的是研究根据肥胖症对男性LUTS进行药物治疗后疗效和生活质量满意度方面的差异。方法进行了为期8周的前瞻性研究,研究对象为140名年龄在50岁以上,国际前列腺症状评分(IPSS)> 12分且前列腺体积> 20 mL的患者。肥胖由体重指数(BMI)或腰围(WC)决定。根据BMI或WC将患者分为2组。患者接受坦索罗辛的剂量为0.4?mg,持续8?周。分析了IPSS与基线相比的变化,最大尿流率(Qmax),排尿后残留量,生活质量问卷(QoL)和国王健康问卷(KHQ)。结果在150名入组患者中,有96名完成了研究。 BMI≥23?kg / m 2 的患者有75名(78.1%),而WC> 90?cm的有24名(25.0%)。总体而言,IPSS,IPSS QoL和总KHQ表现出显着改善。肥胖(BMI≥23?kg / m 2 )和非肥胖(BMI 2 )均显示IPSS和IPSS QoL得分有所改善,但只有肥胖(BMI≥23? kg / m 2 )组显示总KHQ评分改善(P 90?cm)组显示IPSS和总KHQ评分改善(P结论我们的初步研究表明,α-能够根据肥胖改善LUTS和生活质量的阻断剂。由BMI或WC定义的肥胖患者显示出更有利于改善LUTS和生活质量的趋势。试验注册当前对照试验2010-058。2010年9月2日在Soonchunhyang进行注册大学医院

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号